Review article: colitis-associated cancer -- time for new strategies.
AffiliationDepartment of Medicine, Cork University Hospital and University College Cork,, National University of Ireland, Ireland. email@example.com
MeSHAnticarcinogenic Agents/therapeutic use
Colorectal Neoplasms/etiology/*prevention & control
MetadataShow full item record
CitationAliment Pharmacol Ther. 2003 Sep;18 Suppl 2:6-9.
JournalAlimentary pharmacology & therapeutics
AbstractColorectal cancer (CRC) remains a feared and potentially life-threatening complication of both ulcerative colitis and Crohn's colitis. Currently, the main preventive strategy is a secondary one, i.e. surveillance colonoscopy usually after 8 years of disease duration, when the risk for neoplasia begins to increase. Despite its widespread acceptance, dysplasia and cancer surveillance is unproven in terms of reducing mortality or morbidity and there is a remarkable lack of uniformity in the manner in which it is practised. In this review article, the pitfalls of dysplasia surveillance are summarized and the need for novel chemopreventive and perhaps pharmabiotic approaches for prevention are highlighted.
- Ulcerative colitis-associated colorectal cancer.
- Authors: Yashiro M
- Issue date: 2014 Nov 28
- Preventing neoplastic progression in ulcerative colitis.
- Authors: Ullman TA
- Issue date: 2005 Apr
- Reduction of colorectal cancer risk in patients with Crohn's disease.
- Authors: Lichtenstein GR
- Issue date: 2002
- Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
- Authors: Lopez A, Collet-Fenetrier B, Belle A, Peyrin-Biroulet L
- Issue date: 2016 Jun
- Dysplasia in inflammatory bowel diseases.
- Authors: Mescoli C, Albertoni L, D'incá R, Rugge M
- Issue date: 2013 Mar